ADX 097

Q32 Bio announces strategic restructuring to focus on bempikibart development for alopecia areata, discontinuing its ADX-097 renal trials to extend cash runway through 2026.

Q32 Bio has postponed the Phase 2 clinical trial of ADX-097 for ANCA-associated vasculitis (AAV), initially expected to begin in 2025, without providing a new timeline.

Q32 Bio's bempikibart failed to meet the primary endpoint in a Phase 2 trial for atopic dermatitis, leading to a significant drop in the company's stock value.

Q32 Bio's bempikibart Phase 2 trials in atopic dermatitis and alopecia areata are on track, with topline results expected in December 2024.

The complement inhibitors market is experiencing growth due to increased understanding of the complement system's role in rare and chronic diseases.